Related Experiment Videos
Invasive Aspergillus infections in hematologic malignancy patients
Sofia Perea1, Thomas F Patterson
1Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, 78229-3900, USA.
Seminars in Respiratory Infections
|June 19, 2002
Summary
Invasive Aspergillus infections are rising in hematologic malignancy patients. Early diagnosis and new antifungal treatments are crucial for improving outcomes in aspergillosis.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Invasive Aspergillus infections (IA) pose a growing threat to patients with hematologic malignancies.
- Aspergillus fumigatus is the most common causative species, leading to pulmonary and systemic infections.
Purpose of the Study:
- To review the current landscape of invasive aspergillosis in hematologic patients.
- To discuss diagnostic strategies, available and investigational treatments, and preventive measures.
Main Methods:
- Literature review of invasive aspergillosis diagnosis and treatment.
- Analysis of current and emerging antifungal therapies and preventive strategies.
Main Results:
- Definitive diagnosis relies on tissue invasion and positive cultures; circulating fungal antigens and DNA offer promising rapid detection.
- Current treatments include amphotericin B, itraconazole, and caspofungin; new agents like voriconazole and posaconazole are under investigation.
- Preventive measures involve environmental control (HEPA filtration) and antifungal prophylaxis, though the latter is not standardized for high-risk patients.
Conclusions:
- Prompt diagnosis and appropriate antifungal therapy significantly improve prognosis for IA patients.
- A combination of environmental controls, effective diagnostics, and optimized antifungal strategies is essential for managing IA in this vulnerable population.